Miss Mrinmayee Dhar

Mrinmayee Dhar is a clinical and translational researcher focused on vaccine safety, immunogenicity, and public health in the context of COVID-19. Her work is closely associated with multicenter clinical trials in South Africa, particularly evaluating booster strategies following Ad26.COV2.S vaccination. She contributes to studies addressing immune responses in diverse populations, including people living with HIV.

Her publications examine heterologous and homologous booster regimens, fractional dosing, and the durability of humoral and cellular immunity. Through detailed analyses of antibody binding, neutralization, ADCC activity, and T-cell responses, she has helped clarify the comparative performance of mRNA and adenoviral vector boosters in settings of hybrid immunity. Her research also explores anti-vector immunity and its clinical relevance.

In addition, Dhar has investigated coagulation markers such as D-dimer levels following booster vaccination, contributing to evidence on vaccine safety and thrombotic risk in low-risk adults. The current profile is based on a limited number of recent publications, which collectively highlight her strengths in clinical trial methodology, immunological assessment, and evidence-based vaccine policy support.